Identifying and managing depression in women

Journal of Managed Care Pharmacy

Volumn 13, Issue 9 SUPPL. A, 2007, Pages

  Toney, Sam D ^a  

^a Health Integrated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; IMIPRAMINE; METHYLDOPA; MOCLOBEMIDE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ABSENTEEISM; ARTICLE; CASE STUDY; CHRONIC DISEASE; COMORBIDITY; DEPRESSION; FEMALE; GOAL ATTAINMENT; HAMILTON SCALE; HEALTH CARE COST; HEALTH STATUS; HOSPITAL ADMISSION; HUMAN; MANAGED CARE; MENTAL DISEASE; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT EDUCATION; PHYSICAL DISEASE; PREVALENCE; PRIMARY MEDICAL CARE; PRODUCTIVITY; PSYCHOTHERAPY; REMISSION; SUICIDE; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

EID: 38149006848     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.9-a.16     Document Type: Article

References (51)

1. Riolo SA, Nguyen TA, Greden JF, King CA. Prevalence of depression by race/ethnicity: findings from the National Health and Nutrition Examination Survey III. Am J Pub Health. 2005;95:998-1000.
2. Bhatia SC, Bhatia SK. Depression in women: diagnostic and treatment considerations. Am Fam Physician. 1999;60:225-40.
3. Kendler KS, Thornton LM, Gardner CO, et al. Genetic risk, number of previous depressive episodes, and stressful life events in predicting onset of major depression. Am J Psychiatry. 2001;158:582-86.
4. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal Status with depressed mood in women with no history of depression. Arch Gen Psychiatry. 2006;63:375-82.
5. Merikangas KR, Zhang H, Avenevoli S, Acharyya S, Neuenschwander M, Angst J. Longitudinal trajectories of depression and anxiety in a prospective community study. Arch Gen Psychiatry. 2003;60:993-1000.
6. Gonzalez JS, Safren SA, Caagliero E, et al. Depression, self-care, and medication adherence in type 2 diabetes: relationships across the full range of symptom severity. Diabetes Care. Published ahead of print. May 29, 2007, as dc 07-0158.
7. Remick RA. Diagnosis and management of depression in primary care: a clinical update and review. CMAJ. 2002;167:1253-60.
8. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64:1465-75.
9. Stewart W, Ricci JA, Chee E, Hahn S, Morganstein D. Cost of lost productive work time among US workers with depression. JAMA. 2003;289:3135-44.
10. Han D, Wang EC. Remission from depression: a review of venlafaxine clinical and economic evidence. Pharmacoeconomics. 2005;23:567-81.
11. Greenberg P, Corey-Lisle PK, Birnbaum H, Marynchenko M, Claxton A. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics. 2004;22:363-73.
12. Berndt ER, Koran LM, Finkelstein SN, et al. Lost human capital from early-onset chronic depression. Am J Psychiatry. 2000;157:940-47.
13. Ostacher MJ. Comorbid alcohol and substance abuse dependence in depression: impact on the outcome of antidepressant treatment. Psychiatr Clin North Am. 2007;30:69-76.
14. Clouse RE, Lustman PJ, Freekland K, Griffith LS, McGill JB, Carney RM. Depression and coronary heart disease in women with diabetes. Psychosomatic Medicine. 2003;65:376-83.
15. Katon W, Simon G, VonKorff M, et al. Behavioral and clinical factors associated with depression among individuals with diabetes. Diabetes Care. 2004;27:914-20.
16. Nicols GA, Brown JB. Unadjusted and adjusted prevalence of diagnosed depression in type 2 diabetes. Diabetes Care. 2003;26:744-49.
17. Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord. 2002,70:19-26.
18. Kahl KG, Bester M, Greggersen W, et al. Visceral fat deposition and insulin sensitivity in depressed women with and without comorbid borderline personality disorder. Psychosom Med. 2005;67:407-12.
19. Petrlová B, Rosolova H, Hess Z, Podlipný J, Simon J. Depressive disorders and the metabolic syndrome of insulin resistance. Semin Vasc Med. 2004;4:161-65.
20. Jones DJ, Bromberger JT, Sutton-Tyrrell K, Matthews KA. Lifetime history of depression and carotid atherosclerosis in middle-aged women. Arch Gen Psychiatry. 2003;60:153-60.
21. Agatisa PK, Matthews KA, Bromberger JT, Edmundowicz D, Chang Y, Sutton-Tyrrell K. Coronary and aortic calcification in women with a history of major depression. Arch Intern Med. 2005;165:1229-36.
22. Wassertheil-Smoller S, Shumaker S, Ockene J, et al. Depression and cardiovascular seque'lae in postmenopausal women. The Women's Health Initiative (WHI). Arch Intern Med. 2004;164:289-98.
23. Roy A. Suicide. In: Kaplan HI, Sadock BJ, eds. Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. 8th ed. Baltimore, MD: Williams & Wilkins; 1998:867-72.
24. Lyness JM, Cornwell Y, Nelson JC. Suicide attempts in elderly psychiatric inpatients. J Am Geriatr Soc. 1992;40(4):320-24.
25. Mann JJ, Waternaux C, Haas GL, et al. Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry. 1999;156(2):181-89.
26. Conner KR, Cox C, Duberstein PR, et al. Violence, alcohol, and completed suicide: a case-control study. Am J Psychiatry. 2001;158(10):1701-05.
27. Jamison KR. Suicide and manic-depressive illness. In: Jacobs DG, ed. The Harvard Medical School Guide to Suicide Assessment and Intervention. San Francisco: Jossey-Bass; 1999:255-56.
28. Kroll J. Use of no-suicide contracts by psychiatrists in Minnesota. Am J Psychiatry. 2000;157(10):1684-86.
29. American Psychological Association. APA briefing sheet. Women & depression. Available at: www.apa.org/ppo/issues/pwomenanddepress.html. Accessed June 1, 2007.
30. Gullick EL, King LJ. Appropriateness of drugs prescribed by primary care physicians for depressed outpatients. J Affect Disord. 1979;1:55-58.
31. Johnson D. Study of the use of antidepressant medication in general practice. Br J Psychiatry. 1974;125:186-212.
32. Popkin MK, Callies AL. Psychiatric consultation to inpatients with early onset type I diabetes mellitus in a university hospital. Arch Gen Psychiatry. 1987;44:169-71.
33. Magruder-Habib K, Zung WWK, Feussner JR, Alling WC, Saunders WB, Stevens HA. Management of general medical patients with symptoms of depression. Gen Hosp Psychiatry. 1989;11:201-06.
34. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-105.
35. McIntyre RS, Muller A, Mancini D, Silver E. What to do if an initial antidepressant fails? Can Fam Physician. 2003;49:449-57.
36. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 2nd ed. April 2000. In: Practice Guidelines for the Treatment of Psychiatric Disorders Compendium. Washington, DC: American Psychiatric Association; 2004.
37. Depression Guideline Panel. Depression in primary care: volume 2. Treatment of major depression. Clinical practice guideline, number 5. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; April 1993. AHCPR publication no. 93-0551.
38. Williams JW, Barrett J, Oxman T, et al. Treatment of dysthmia and minor depression in primary care: a randomized controlled trial in older adults. JAMA. 2000;284:1519-26.
39. Stafford RS, MacDonald EA, Finkelstein SN. National patterns of medication treatment for depression, 1987 to 2001. Prim Care Companion J Clin Psychiatry. 2001;3(6):232-35.
40. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000;157:1445-52.
41. Hildebrandt MG, Steyererg EW, Stage KB, Passchier J, Kragh-Soerensoen for the Danish University Antidepressant Group. Are gender differences important for the clinical effects of antidepressants? Am J Psychiatry. 2003;160:1643-50.
42. The pharmacologic management of major depression in the primary care setting. Washington DC: Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel, Veterans Health Administration, Department of Veterans Affairs; May 2000. PBM-MAP publication no. 00-0016.
43. Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med. 2000;343:1942-50.
44. Boudreau DM, Capoccia KL, Sullivan SD, et al. Collaborative care model to improve outcomes in major depression. Ann Pharmacother. 2002;36:585-91.
45. Frank E. Enhancing patient outcomes: treatment adherence. J Clin Psychiatry. 1997;58(suppl 1):11-14.
46. Bucci KK, Possidente CJ, Talbot KA. Strategies to improve medication adherence in patients with depression. Am J Health-Syst Pharm. 2005;60:2601-05.
47. McElroy SL, Keck PE Jr, Friedman LM. Minimizing and managing antidepressant side effects. J Clin Psychiatry. 1995;56(suppl 2):49-55.
48. Fava M, Graves L, Benazzi F, et al. A cross-sectional study of the prevalence of cogninve and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry. 2006; 67(11):1754-59.
49. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Editon, Text Revision. (DSM-IV-TR). 2000. Arlington, VA.
50. Cadieux RJ. Practical management of treatment-resistant depression. Am Fam Physician. 1998;58:2059-62.
51. Corey-Lisle PK, Nash R, Stang P, Swindle R. Response, partial response, and nonresponse in primary care treatment of depression. Arch Int Med. 2004;164:1197-204.